UGT1A1 and neutropenia: In particular, the incidence of grade 4 neutropenia was significantly higher in patients with UGT1A1*1/*6 genotype in the QUATTRO trial that evaluated GONO-triplet regimen plus bevacizumab for Japanese mCRC patients [13].